Almost all patients with EGFR-positive NSCLC had adenocarcinomas (386 patients [99.2%]) whereas 56 patients with wildtype EGFR NSCLC (16.8%) had squamous cell carcinoma (P < .001). This evidence concerns the gene EGFR and adenocarcinoma.